 |
市场调查报告书
商品编码
1698589
抗忧郁药物市场机会、成长动力、产业趋势分析及 2025-2034 年预测Antidepressant Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 |
||||||
2024 年全球抗忧郁药物市场规模达到 187 亿美元，预计 2025 年至 2034 年期间的复合年增长率将达到 7.5%。这一增长主要得益于人们对心理健康的日益关注以及对抑郁症及相关疾病有效治疗的需求日益增长。药物研究的不断进步推出了针对难治性忧郁症的创新药物，可以更快地缓解病情并提高耐受性。仿製抗忧郁药物的普及提高了人们的负担能力，特别是在中低收入地区，而远距医疗和网路药局使服务不足地区的个人更容易获得心理健康治疗。
抗忧郁药物调节影响情绪、情绪和行为的神经传导物质。全球市场根据药物类别进行细分，选择性血清素再摄取抑制剂 (SSRI) 在 2024 年占据 55.8% 的主导市场。其广泛使用归因于高效能、副作用少以及在治疗忧郁症、焦虑症、强迫症、恐慌症和创伤后压力症候群方面的广泛适用性。通用版本的推出提高了药物的可及性和可负担性，进一步巩固了其市场地位。
| 市场范围 | |
|---|---|
| 起始年份 | 2024 |
| 预测年份 | 2025-2034 |
| 起始值 | 187亿美元 |
| 预测值 | 379亿美元 |
| 复合年增长率 | 7.5％ |
根据应用，市场分为广泛性焦虑症、重度忧郁症、强迫症、恐慌症和其他病症。重度忧郁症领域引领市场，到 2024 年将达到 95 亿美元。随着人们认识的提高和对忧郁症的耻辱感的减少，越来越多的人寻求医疗帮助，从而导致诊断率更高，对抗忧郁药物的需求持续增加。长期治疗的必要性进一步推动了该领域的成长。
根据给药途径，市场分为口服、注射、鼻腔和透皮製剂。口服药物在 2024 年占据了相当大的市场份额，预计到 2034 年将达到 302 亿美元。由于服用方便、价格实惠且安全性得到确认，药片和胶囊仍然是首选。品牌和仿製口服抗忧郁药物均能确保患者广泛获得药物，从而促进该领域继续占据主导地位。
就药物类型而言，市场分为品牌药和仿製药。受益于强大的行销策略、品牌忠诚度以及针对难治性忧郁症的创新，预测期内品牌细分市场预计将以 7.2% 的复合年增长率成长。品牌药物通常被认为具有卓越的疗效和安全性，因此其采用率不断提高。
分销管道包括医院药房、零售药房和网路药房。由于严重精神疾病的处方量很大，医院药局在 2024 年占了 57.9% 的市场。这些药房提供专门的药物，透过仔细的监测和治疗调整确保更好地管理患者。对专业心理健康服务的日益关注继续支持市场扩张。
2024 年，美国抗忧郁药物市值为 68 亿美元。精神健康障碍的高盛行率，加上人们意识的提高和医疗保健体系的发达，推动了市场的成长。透过初级保健医生和心理健康专家可以获得抗忧郁药物，确保了需求的稳定成长。
目录
第一章：方法论与范围
第二章：执行摘要
第三章：行业洞察
- 产业生态系统分析
- 产业衝击力
- 成长动力
- 忧郁症和焦虑症盛行率上升
- 增加研发投入
- 对治疗疗法和心理健康的认识不断提高
- 产业陷阱与挑战
- 一些抗忧郁药物的副作用
- 顾客对非药物疗法的偏好高于药物疗法
- 成长动力
- 成长潜力分析
- 监管格局
- 管道分析
- 波特的分析
- PESTEL分析
第四章：竞争格局
- 介绍
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 策略仪表板
第五章：市场估计与预测：按药物类别，2021 年至 2034 年
- 主要趋势
- 选择性血清素再摄取抑制剂（SSRI）
- 血清素和正肾上腺素再摄取抑制剂（SNRI）
- 三环抗忧郁剂 (TCA)
- 非典型抗忧郁药
- 去甲肾上腺素多巴胺再摄取抑制剂 (NDRI)
- 单胺氧化酶抑制剂（MAOI）
- 其他药物类别
第六章：市场估计与预测：按应用，2021 年至 2034 年
- 主要趋势
- 重度忧郁症
- 广泛性焦虑症
- 强迫症
- 恐慌症
- 其他应用
第七章：市场估计与预测：依管理路线，2021 年至 2034 年
- 主要趋势
- 口服
- 注射剂
- 鼻腔
- 透皮
第八章：市场估计与预测：按药物类型，2021 年至 2034 年
- 主要趋势
- 品牌
- 通用的
第九章：市场估计与预测：按配销通路，2021 年至 2034 年
- 主要趋势
- 医院药房
- 零售药局
- 网路药局
第十章：市场估计与预测：按地区，2021 年至 2034 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 荷兰
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
第 11 章：公司简介
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Intra-Cellular Therapies
- Janssen Pharmaceuticals
- NV Organon
- Novartis
- Opko Health
- Otsuka Pharmaceutical
- Patheon
- Pfizer
- Sandoz
- Sun Pharmaceuticals
- Takeda Pharmaceuticals
- Zhejiang NHU Company
The Global Antidepressant Drugs Market reached USD 18.7 billion in 2024 and is projected to expand at a CAGR of 7.5% between 2025 and 2034. This growth is largely driven by the rising focus on mental health and the increasing need for effective treatments for depression and related disorders. Continuous advancements in pharmaceutical research have introduced innovative drugs targeting treatment-resistant depression, providing faster relief with improved tolerability. The availability of generic antidepressants has enhanced affordability, particularly in low- and middle-income regions, while telemedicine and online pharmacies have made mental health treatments more accessible to individuals in underserved areas.
Antidepressant drugs regulate neurotransmitters that influence mood, emotions, and behavior. The global market is segmented based on drug class, with selective serotonin reuptake inhibitors (SSRIs) holding a dominant 55.8% market share in 2024. Their widespread use is attributed to high efficacy, fewer side effects, and broad applicability in treating depression, anxiety, obsessive-compulsive disorder, panic disorder, and post-traumatic stress disorder. The availability of generic versions has further strengthened their market position by improving accessibility and affordability.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $18.7 Billion |
| Forecast Value | $37.9 Billion |
| CAGR | 7.5% |
Based on application, the market is categorized into generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, panic disorder, and other conditions. The major depressive disorder segment led the market, reaching USD 9.5 billion in 2024. As awareness grows and the stigma around depression declines, more people seek medical assistance, leading to higher diagnosis rates and sustained demand for antidepressant medications. The necessity for long-term treatment further drives growth in this segment.
The market is divided by route of administration into oral, injectable, nasal, and transdermal formulations. The oral segment accounted for a significant portion of the market in 2024 and is projected to reach USD 30.2 billion by 2034. Tablets and capsules remain the preferred choice due to ease of administration, affordability, and established safety profiles. Both branded and generic oral antidepressants contribute to the segment's continued dominance by ensuring broad accessibility for patients.
Regarding medication type, the market is split into branded and generic drugs. The branded segment is expected to grow at a 7.2% CAGR during the forecast period, benefiting from strong marketing strategies, brand loyalty, and innovations aimed at treatment-resistant depression. Branded medications are often perceived as offering superior efficacy and safety, contributing to their increasing adoption.
Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies held a 57.9% market share in 2024 due to the high volume of prescriptions for severe mental health conditions. These pharmacies offer specialized medications, ensuring better patient management through careful monitoring and treatment adjustments. A growing focus on specialized mental health services continues to support market expansion.
The U.S. antidepressant drugs market was valued at USD 6.8 billion in 2024. The high prevalence of mental health disorders, coupled with increasing awareness and a well-developed healthcare system, drives market growth. The accessibility of antidepressants through primary care physicians and mental health specialists ensures a steady rise in demand.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of depression and anxiety disorders
- 3.2.1.2 Increasing investment in research and development
- 3.2.1.3 Growing awareness regarding treatment therapies and mental health
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Side effects associated with some antidepressant drugs
- 3.2.2.2 Customer preference for non-pharmacological therapeutics over pharmacological therapeutics
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Selective serotonin reuptake inhibitors (SSRIs)
- 5.3 Serotonin and noradrenaline reuptake inhibitors (SNRIs)
- 5.4 Tricyclic antidepressants (TCAs)
- 5.5 Atypical antidepressants
- 5.6 Norepinephrine-dopamine reuptake inhibitor (NDRI)
- 5.7 Monoamine oxidase inhibitors (MAOIs)
- 5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Major depressive disorder
- 6.3 Generalized anxiety disorder
- 6.4 Obsessive-compulsive disorder
- 6.5 Panic disorder
- 6.6 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Injectable
- 7.4 Nasal
- 7.5 Transdermal
Chapter 8 Market Estimates and Forecast, By Medication Type, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Branded
- 8.3 Generic
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 Hospital pharmacies
- 9.3 Retail pharmacies
- 9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Netherlands
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
Chapter 11 Company Profiles
- 11.1 Bristol-Myers Squibb
- 11.2 Eli Lilly and Company
- 11.3 GlaxoSmithKline
- 11.4 Intra-Cellular Therapies
- 11.5 Janssen Pharmaceuticals
- 11.6 N.V. Organon
- 11.7 Novartis
- 11.8 Opko Health
- 11.9 Otsuka Pharmaceutical
- 11.10 Patheon
- 11.11 Pfizer
- 11.12 Sandoz
- 11.13 Sun Pharmaceuticals
- 11.14 Takeda Pharmaceuticals
- 11.15 Zhejiang NHU Company
